telitacicept
remegen
['telitacicept']
wu et al phase 3 rct of telitacicept (targets blys and april) in sle. primary endpoint met at week 52! sri(4) 67% vs 33% or 83% vs 38% (p&lt;0.001 for both) depending on how you want to slice it. #acr22 abstr#l07 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC